XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (14756)	9/19/2000 6:07:23 PM
From: Cacaito	Read Replies (1) of 17367

"Because neurological or organ dysfunction had not been prospectively defined and collected as endpoints on the case-report forms, information on their occurrence was captured from the adverse-events report forms." " However, the use of adverse-event data caused problems since it combined a myriad of inconsequential events with major morbidities such as severe amputation. The results of this composite endpoint analysis are included for completeness, but are recognised as methodologically FLAWED and were not included in the prospective trial design NOR AGREED to by the clinical investigators." " Additionally, an analysis of the composite endpoint, including only endpoints that were prospectively defined in the protocol individually (death, amputations, and POPC), and which are the most clinically meaningful, is presented for comparison." I read the full article. The not prospectively design " flawed composite endpoint" was not agreed to by clinical investigators, and it showed one of the worst "p" (p = 0.74) a BIG IRONY cause the prospectively design endpoints when "composite analysis" was done showed a favorable trend p = 0.07, still not the magic 0.05 or less.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next